High rate of indigenous bronchiolitis and palivuzumab [5]

Journal of Paediatrics and Child Health

Volumn 37, Issue 4, 2001, Pages 416-417

  Whitehall, J S ^a   Bolisetty, S ^a   Whitehall, J P ^a   Francis, F ^a   Norton, R ^a   Patole, S K ^a  

^a TOWNSVILLE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

PALIVIZUMAB; STEROID;

ANTIBIOTIC THERAPY; BRONCHIOLITIS; CHILD HOSPITALIZATION; COST EFFECTIVENESS ANALYSIS; DRUG COST; HUMAN; IMMUNOFLUORESCENCE TEST; IMMUNOPROPHYLAXIS; LETTER; OXYGEN THERAPY; PREMATURITY; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; VIRUS TRANSMISSION;

EID: 0034890306     PISSN: 10344810     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1754.2001.0720f.x     Document Type: Letter

References (5)

1. Hospitalisation for RSV infection in ex-preterm infants - Implications for use of RSV immune globulin
2. Rehospitalization for respiratory syncytial virus among premature infants
3. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high risk infants
4. The cost effectiveness of varicella vaccine programmes for Australia
5. Respiratory syncytial virus, a continuing culprit and conundrum